MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

CymaBay Therapeutics Company Profile (NASDAQ:CBAY)

Consensus Ratings for CymaBay Therapeutics (NASDAQ:CBAY) (?)
Ratings Breakdown: 1 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $3.13 (74.58% upside)

Analysts' Ratings History for CymaBay Therapeutics (NASDAQ:CBAY)
Show:
DateFirmActionRatingPrice TargetActions
6/1/2016HC WainwrightDowngradeBuy -> Neutral$6.00 -> $2.25View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/21/2015Piper JaffrayInitiated CoverageOverweight$4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/8/2015Stifel NicolausReiterated RatingBuy$15.00 -> $9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/18/2015Roth CapitalSet Price TargetBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/15/2014Cowen and CompanyBoost Price TargetOutperform$9.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/25/2014 forward)
Earnings History for CymaBay Therapeutics (NASDAQ:CBAY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/12/2016Q1($0.28)($0.29)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/29/2016Q4($0.35)($0.26)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q315($0.33)($0.27)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.42)($0.09)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015($0.43)($0.44)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/18/2015Q414($0.47)($0.87)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2014Q314($0.47)($0.44)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for CymaBay Therapeutics (NASDAQ:CBAY)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for CymaBay Therapeutics (NASDAQ:CBAY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for CymaBay Therapeutics (NASDAQ:CBAY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
4/15/2016Charles McwherterVPBuy3,000$1.68$5,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/5/2016Sujal ShahCFOBuy55,000$1.39$76,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/4/2016Sujal ShahCFOBuy22,000$1.39$30,580.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/11/2015Carl GoldfischerDirectorSell46,729$2.74$128,037.46View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2015Emster Kurt VonDirectorBuy90,000$2.69$242,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/20/2015Emster Kurt VonDirectorBuy1,600,000$2.81$4,496,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/18/2015Sujal ShahCFOBuy10,000$3.40$34,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/18/2015Wart Harold VanCEOBuy7,500$3.34$25,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2015Charles McwherterVPBuy2,000$3.16$6,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for CymaBay Therapeutics (NASDAQ:CBAY)
DateHeadline
06/21/16 02:57 PMStrong Buy Calls Count For Cymabay Therapeutics Inc. (NASDAQ:CBAY) At 1 - Investor Newswire
06/06/16 03:33 PMCYMABAY THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/06/16 08:03 AMBiolife (BLFS), Ardelyx (ARDX), Synchronoss (SNCR) are Big Moving Stocks Today
06/02/16 09:08 PMAnalysts Rating Review: CymaBay Therapeutics Inc (NASDAQ:CBAY) - The Point Review - The Point ReviewAnalysts Rating Review: CymaBay Therapeutics Inc (NASDAQ:CBAY)The Point ReviewCymaBay Therapeutics Inc (NASDAQ:CBAY) received “Downgrade” rating by H.C. Wainwright in a research note issued to investors on Jun-01-16 from Buy to Neutral at $2.25. Analysts presently have a $5.00 price target on the company's stock, however ...CymaBay Therapeutics Inc. (NASDAQ: CBAY)'s Buries Phase 2 Study Of MBX-8025, Now What?Scibility MediaCymabay Therapeutics Inc. (CBAY) Updated Analyst CoverageRisers & FallersCymaBay Therapeutics Inc (CBAY) Lowered to Neutral at HC WainwrightLet Me Know About ThisMarket Digest -Share Trading News -News Tribuneall 17 news articles »
06/02/16 03:13 PMMost Recent Stocks Movements: Cymabay Therapeutics Inc. (NASDAQ:CBAY) , Juno Therapeutics, Inc. (NASDAQ ... - Street Updates - Most Recent Stocks Movements: Cymabay Therapeutics Inc. (NASDAQ:CBAY) , Juno Therapeutics, Inc. (NASDAQ ...Street UpdatesOn 6/1/2016, Cymabay Therapeutics Inc. (NASDAQ:CBAY) highlighted downward shift of -18.85% or -0.46 points to $1.98. The company traded a volume of 1.18 million shares over average volume of 433.99 thousand shares. Trailing twelve month period, ...and more »
06/02/16 11:51 AMInsiders Are Gradually Buying Cymabay Therapeutics, Inc. (NASDAQ:CBAY) - HNN - Insiders Are Gradually Buying Cymabay Therapeutics, Inc. (NASDAQ:CBAY)HNNAccording to the latest SEC filings, insiders at Cymabay Therapeutics, Inc. (NASDAQ:CBAY) have increased their position in the stock by 36.63% over the past 6 months. Insiders now own 1.00% of total outstanding shares. There are both legal and illegal ...and more »
06/02/16 11:51 AMCymaBay Therapeutics Inc. (NASDAQ: CBAY)'s Buries Phase 2 Study Of MBX-8025, Now What? - Scibility Media - Scibility MediaCymaBay Therapeutics Inc. (NASDAQ: CBAY)'s Buries Phase 2 Study Of MBX-8025, Now What?Scibility MediaAccording to CymaBay Therapeutics Inc. (NASDAQ: CBAY), MBX-8025 showed improvement in patients afflicted by PBC. In particular, the compound showed improvements in cholestasis biochemical markers, which was the target of the proof-of-concept ...Analysts Rating Review: CymaBay Therapeutics Inc (NASDAQ:CBAY)The Point ReviewCymaBay Therapeutics Inc (CBAY) Lowered to Neutral at HC WainwrightLet Me Know About ThisCymaBay Therapeutics Inc (CBAY) is Downgraded by H.C. Wainwright to Neutral, Price Target at $2.25Market DigestShare Trading News -News Tribune -Franklin Independentall 16 news articles »
06/01/16 09:12 PMTrader's Buzzer: Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), CymaBay Therapeutics Inc (NASDAQ:CBAY), Ampliphi ... - The Point Review - The Point ReviewTrader's Buzzer: Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), CymaBay Therapeutics Inc (NASDAQ:CBAY), Ampliphi ...The Point ReviewShares of CymaBay Therapeutics Inc (NASDAQ:CBAY) slipped -15.17% to $2.07 at 11:32 AM EDT. The stock exchanged hands of 589,145 shares recently versus average trading capacity of 451,426 shares. However recently the stock touch highest trading ...
06/01/16 03:10 PMCymaBay Therapeutics (CBAY) Ceases MBX-8025 Phase 2 in PBC Early After Primary Objective Met - StreetInsider.com - CymaBay Therapeutics (CBAY) Ceases MBX-8025 Phase 2 in PBC Early After Primary Objective MetStreetInsider.comCymaBay Therapeutics, Inc. (Nasdaq: CBAY) announced that it has discontinued its current Phase 2 study of MBX-8025 in patients with Primary Biliary Cholangitis (PBC) after determining that the study met its objective of establishing proof-of-concept ...Cymabay Therapeutics Inc. (CBAY) Updated Broker RatingsRisers & FallersCymabay Ends Liver Drug Study Early After Proof-Of-Concept Established (NASDAQ:CBAY)Sonoran Weekly ReviewCymaBay Therapeutics announces positive results from mid-stage study of MBX-8025 in PBC; investors wary of side ...Seeking Alphaall 5 news articles »
06/01/16 11:37 AMSemGroup Corporation (NYSE:SEMG) Edged 7.76%: Cymabay Therapeutics, Inc. (NASDAQ:CBAY), Sprint ... - KC Register - SemGroup Corporation (NYSE:SEMG) Edged 7.76%: Cymabay Therapeutics, Inc. (NASDAQ:CBAY), Sprint ...KC RegisterCymabay Therapeutics, Inc. (NASDAQ:CBAY) announced that it has discontinued its current Phase 2 study of MBX-8025 in patients with Primary Biliary Cholangitis (PBC) after determining that the study met its objective of establishing proof-of-concept for ...
06/01/16 11:37 AMCymaBay Therapeutics Inc (CBAY) Lowered to Neutral at HC Wainwright - Let Me Know About This - CymaBay Therapeutics Inc (CBAY) Lowered to Neutral at HC WainwrightLet Me Know About ThisCymaBay Therapeutics logo CymaBay Therapeutics Inc (NASDAQ:CBAY) was downgraded by analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Wednesday. They presently have a $2.25 ...CymaBay Therapeutics Inc (NASDAQ:CBAY)'s Company Shares Decreased 2.79% After High VolatilityHNNCymaBay Therapeutics Announces Top Line Efficacy And Safety Data From Its Phase 2 Study Of Mbx-8025 In Patients ...Clinical LeaderNew Roundup- Golar LNG Ltd. (NASDAQ:GLNG), Uni-Pixel (NASDAQ:UNXL), Cymabay Therapeutics (NASDAQ:CBAY)Seneca GlobeStreet Wise Report (press release) (blog)all 5 news articles »
06/01/16 06:08 AMCymaBay Therapeutics downgraded by H.C. Wainwright -
05/31/16 08:35 AMShare Rating Focus on Cymabay Therapeutics Inc. (NASDAQ:CBAY) - HNN - Share Rating Focus on Cymabay Therapeutics Inc. (NASDAQ:CBAY)HNNThis stock research may entail following what professional equity analysts think about the company. Presently, Wall Street analysts have given a consensus stock rating of 1 on shares of Cymabay Therapeutics Inc. (NASDAQ:CBAY). Covering analysts will ...and more »
05/28/16 09:56 AMBroker Roundup For Cymabay Therapeutics Inc. (CBAY) - Share Trading News - Broker Roundup For Cymabay Therapeutics Inc. (CBAY)Share Trading News08/15/2014 – Cymabay Therapeutics Inc. had its “outperform” rating reiterated by analysts at Cowen. They now have a USD 15 price target on the stock. The share price of Cymabay Therapeutics Inc. (CBAY) was down -1.22% during the last trading session, ...Cymabay Therapeutics, Inc. (NASDAQ:CBAY) earnings expectationsZergwatchInsiders Are Gradually Buying Cymabay Therapeutics, Inc. (NASDAQ:CBAY)Wall Street Hints and Newsall 3 news articles »
05/26/16 07:27 AMCYMABAY THERAPEUTICS, INC. : Regulation FD Disclosure (form 8-K) - CymaBay Therapeutics Inc. (NASDAQ: CBAY) Analyst Cove.. 03/29 CymaBay Reports Fourth Quarter and Full Year 2015 Financial Results 03/29 CYMABAY THERAPEUTICS: Announces the Appointment of Paul F. Truex and Robert J. .. 03/29 CYMABAY THERAPEUTICS ...
05/24/16 07:06 AMCYMABAY THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure -
05/19/16 07:00 AMCymaBay Therapeutics to Present at UBS Global Healthcare Conference - [GlobeNewswire] - NEWARK, Calif., May 19, 2016-- CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, today announced that ...
05/11/16 03:05 PMCYMABAY THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report -
05/02/16 07:00 AMCymaBay to Announce First Quarter 2016 Financial Results on Wednesday, May 11 - [GlobeNewswire] - NEWARK, Calif., May 02, 2016-- CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, today announced that ...
04/25/16 07:31 AMCymaBay Therapeutics Inc. (NASDAQ: CBAY) Analyst Coverage Initiated - [Accesswire] - NEWARK, CA / ACCESSWIRE / April 25, 2016 / CymaBay Therapeutics Inc. (NASDAQ: CBAY) a biopharmaceutical company focused on developing therapies to treat metabolic diseases, including serious rare and orphan ...
03/30/16 03:26 PMEdited Transcript of CBAY earnings conference call or presentation 29-Mar-16 8:30pm GMT -
03/29/16 03:05 PMCYMABAY THERAPEUTICS, INC. Files SEC form 10-K, Annual Report -
03/28/16 03:01 PMCymaBay Announces the Appointment of Paul F. Truex and Robert J. Weiland to its Board of Directors - [GlobeNewswire] - NEWARK, Calif., March 28, 2016-- CymaBay Therapeutics, Inc., today announced the appointment of Paul F. Truex and Robert J. Weiland to the company’ s Board of Directors, effective April 1, 2016.. "I ...
03/14/16 11:54 AMInvestors Are Watching: Bojangles', Inc. (NASDAQ:BOJA), Cymabay Therapeutics, Inc. (NASDAQ:CBAY), Citigroup Inc ... - KC Register - Investors Are Watching: Bojangles', Inc. (NASDAQ:BOJA), Cymabay Therapeutics, Inc. (NASDAQ:CBAY), Citigroup Inc ...KC RegisterCymabay Therapeutics, Inc. (NASDAQ:CBAY) announced that Harold Van Wart, Ph.D., President and Chief Executive Officer, will present a corporate update at the Cowen and Company 36th Annual Health Care Conference on Wednesday, March 9 and at ...and more »
03/03/16 07:00 AMCymaBay Therapeutics to Present at Two Upcoming Investor Conferences in March - [GlobeNewswire] - NEWARK, Calif., March 03, 2016-- CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, today announced that ...
02/13/16 09:22 PMCymabay Therapeutics Incorporated (NASDAQ:CBAY) Short Interest Increased By 33.61% - fdanewsalert.com - Cymabay Therapeutics Incorporated (NASDAQ:CBAY) Short Interest Increased By 33.61%fdanewsalert.comThe short interest to Cymabay Therapeutics Incorporated's float is 1.43%. The stock increased 14.20% or $0.13 on February 12, hitting $1.06. About 154,073 shares traded hands. CymaBay Therapeutics Inc (NASDAQ:CBAY) has declined 60.45% since July ...CymaBay Therapeutics Inc (CBAY) Upgraded to "Buy" at Zacks Investment ResearchFinancial Market NewsInvestment Analysts' Weekly Ratings Changes for CymaBay Therapeutics (CBAY)The Vista Voiceall 3 news articles »
02/08/16 12:56 PMCymabay Therapeutics Incorporated (NASDAQ:CBAY) Shorted Shares Increased 8.26% After Market Selling - fdanewsalert.com - Cymabay Therapeutics Incorporated (NASDAQ:CBAY) Shorted Shares Increased 8.26% After Market Sellingfdanewsalert.comOut of 3 analysts covering Cymabay Therapeutics Inc (NASDAQ:CBAY), 2 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Cymabay Therapeutics Inc was the topic in 2 analyst reports since July 21, 2015 according to StockzIntelligence Inc.and more »
02/04/16 12:28 PMLatest Analysts Reports On Cymabay Therapeutics Inc. (CBAY) - Risers & Fallers - Latest Analysts Reports On Cymabay Therapeutics Inc. (CBAY)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Cymabay Therapeutics Inc. (CBAY). The latest broker reports which have been released state 0 analysts have a rating of “buy”, 2 analysts “outperform”, 0 analysts “hold”, ...What's in CymaBay Therapeutics Inc After Forming Bearish Wedge Down Pattern?WallStreet.orgall 2 news articles »
02/02/16 07:00 AMCymaBay Therapeutics to Present at the BIO CEO & Investor Conference - [GlobeNewswire] - NEWARK, Calif., Feb. 02, 2016-- CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, today announced that ...
02/01/16 11:53 AMCompany Shares of Cymabay Therapeutics Inc. (NASDAQ:CBAY) Rally 9% - Bull Report - Company Shares of Cymabay Therapeutics Inc. (NASDAQ:CBAY) Rally 9%Bull ReportShares of Cymabay Therapeutics Inc. (NASDAQ:CBAY) appreciated by 9% during the past week but lost 35.5% on a 4-week basis. The shares have outperformed the S&P 500 by 7.13% in the past week but underperformed the index by 32.06% in the last 4 ...
01/29/16 04:04 PMCYMABAY THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers -
01/20/16 06:15 PMPre-Open Stock Movers 01/20: (ZFGN) (SYN) (CBAY) Higher; (FTNT) (AMD) (IBM) Lower (more...) - CymaBay Therapeutics, Inc. (NASDAQ: CBAY) 20.4% HIGHER; announced that it has successfully concluded its end-of-phase 2 meeting discussions with the U.S. Food and Drug Administration (FDA) on the Phase 3 development program for arhalofenate. Correspondence ...
01/20/16 11:05 AMCymaBay Therapeutics (CBAY) Concludes End-of-Phase 2 Meeting with FDA for Arhalofenate; Phase 3 Issues Resolved - StreetInsider.com - CymaBay Therapeutics (CBAY) Concludes End-of-Phase 2 Meeting with FDA for Arhalofenate; Phase 3 Issues ResolvedStreetInsider.comCymaBay Therapeutics, Inc. (NASDAQ: CBAY) announced that it has successfully concluded its end-of-phase 2 meeting discussions with the U.S. Food and Drug Administration (FDA) on the Phase 3 development program for arhalofenate. Correspondence ...CymaBay Therapeutics Announces Successful Completion of End-of-Phase 2 Discussions With FDA for ArhalofenateGlobeNewswire (press release)all 5 news articles »
01/20/16 11:05 AMCymaBay Successfully Completes End-of-Phase 2 Discussions With FDA; Stock Surges - (RTTNews.com) - CymaBay Therapeutics, Inc. ( CBAY) said that it has successfully concluded its end-of-phase 2 meeting discussions with the U.S. Food and Drug Administration on the Phase 3 development program for arhalofenate. Correspondence with the FDA ...
01/20/16 07:03 AMCYMABAY THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
01/20/16 07:01 AM8:01 am CymaBay Therapeuticshas Announces Successful Completion of End-of-Phase 2 Discussions With FDA for Arhalofenate; reached agreement with the FDA on all of the key elements of a Phase 3 program that would support registration -
01/20/16 07:00 AMCymaBay Therapeutics Announces Successful Completion of End-of-Phase 2 Discussions With FDA for Arhalofenate - [GlobeNewswire] - NEWARK, Calif., Jan. 20, 2016-- CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, today announced that ...
01/06/16 07:00 AMCymaBay Therapeutics to Present at the Biotech Showcase 2016 - [GlobeNewswire] - NEWARK, Calif., Jan. 06, 2016-- CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, today announced that ...
12/10/15 03:06 AMHedge Funds Aren’t Crazy About FXCM Inc (FXCM) Anymore -
12/08/15 12:17 PMCYMABAY THERAPEUTICS, INC. Financials -
11/13/15 11:00 AMCymaBay Announces Participation at Three Upcoming Investor Conferences - [GlobeNewswire] - NEWARK, Calif. -- CymaBay Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, today announced that management ...
11/12/15 03:09 PMCYMABAY THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an -
11/12/15 03:01 PMCymaBay Announces Third Quarter Financial Results - [GlobeNewswire] - NEWARK, Calif. -- CymaBay Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, today announced financial results ...
11/12/15 06:07 AMQ3 2015 CymaBay Therapeutics Inc Earnings Release - Time Not Supplied -
11/10/15 07:30 AMCymaBay Therapeutics Announces the Initiation of a Phase 2 Study of MBX-8025 in Patients With Primary Biliary Cholangitis/Cirrhosis - [GlobeNewswire] - NEWARK, Calif. -- CymaBay Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, today announced the initiation of ...
11/05/15 07:30 AMCymaBay Therapeutics to Present Results From Two Arhalofenate Phase 2 Studies at the American College of Rheumatology (ACR) Annual Meeting, November 6 - 11 - [GlobeNewswire] - Phase 2 Flare Study Results Demonstrate that Arhalofenate Reduces Flares while Lowering Serum Uric Acid in Gout Patients
11/04/15 07:30 AMCymaBay to Announce Third Quarter 2015 Financial Results on Thursday, November 12 - [GlobeNewswire] - NEWARK, Calif. -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, today announced that ...
10/26/15 02:23 PMLifeSci Capital Initiates Coverage of CymaBay Therapeutics - [Accesswire] - Developing therapies for Metabolic and Orphan Diseases; Report Available here: http://www.lifescicapital.com/equity-research/cymabay/ NEW YORK, NY / ACCESSWIRE / October 26, 2015 / LifeSci Capital, LLC, ...
10/21/15 09:51 AMFDA reviewers question safety of AstraZeneca's gout drug -
About CymaBay Therapeutics

CymaBay Therapeutics logoCymaBay Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan disorders. Arhalofenate, the Company's lead product candidate, is used to treat gout. The Company has completed five Phase II clinical trials of Arhalofenate in patients with gout. The Company's second product candidate, MBX-8025, is used to treat disorder linked to deficits in lipid storage, handling and utilization, many of which result in metabolic disorders. The Company has completed five Phase I and one Phase II clinical trials of MBX-8025. The Company's MBX-2982 is a treatment for type 2 diabetes that targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion. MBX-2982 has completed four Phase I studies and one Phase II study.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CBAY
  • CUSIP:
Key Metrics:
  • Previous Close: $1.79
  • 50 Day Moving Average: $2.11
  • 200 Day Moving Average: $1.65
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $41.97M
  • Current Quarter EPS Consensus Estimate: $-1.25 EPS
Additional Links:
CymaBay Therapeutics (NASDAQ:CBAY) Chart for Saturday, June, 25, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha